Invasive candidiasis: Turning risk into a practical prevention policy?

Clinical Infectious Diseases

Volumn 33, Issue 2, 2001, Pages 187-190

  Sobel, Jack D ^a   Rex, John H ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; EDITORIAL; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MEDICAL PRACTICE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FUNGEMIA; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; UNITED STATES;

EID: 0035879459     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321812     Document Type: Editorial

References (33)

1. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
2. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
3. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
4. Anti-fungal prophylaxis in neutropenic cancer patients: A meta-analysis
5. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
6. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
7. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
8. Risk factors for hospital-acquired candidemia: A matched case-control study
9. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia
10. Candida colonization and subsequent infections in critically ill surgical patients
11. Candida infections in critically ill trauma patients: A retrospective case-control study
12. Risk factors for candidemia in a children's hospital
13. Clinical significance of Candida isolated from peritoneum in surgical patients
14. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients
15. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study
16. APACHE II: A severity of disease classification system
17. Fungaemia and funguria after oral administration of Candida albicans
18. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia therapy in adults
19. Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens
20. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies
21. Proposed mechanisms for the translocation of intestinal bacteria
22. Management of deep candida infection in surgical and intensive care unit patients
23. Practice guidelines for the treatment of candidiasis
24. Epidemiology, diagnosis and treatment of systemic candida infection in surgical patients under intensive care
25. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial
26. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients
27. Fluconazole prevents severe Candida spp infections in high-risk critically ill patients: A randomized, double-blind, placebo-controlled study
28. A double-blind placebo controlled trial of prophylactic fluconazole to prevent Candida infections in critically ill surgical patients
29. Fluconazole prophylaxis for high-risk liver transplant recipients
30. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: A randomized, placebo-controlled study
31. Low-dose amphotericin B for the prophylaxis of serious Candida infections in high-risk liver recipients
32. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial
33. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome